Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Leukemia, Myeloid, Acute D015470 19 associated lipids
Respiratory Hypersensitivity D012130 18 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Hyperaldosteronism D006929 4 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Agranulocytosis D000380 7 associated lipids
Streptococcal Infections D013290 4 associated lipids
Shock D012769 11 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Polycythemia Vera D011087 13 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Filep J and Rosenkranz B Mechanism of vasopressin-induced platelet aggregation. 1987 Thromb. Res. pmid:3105115
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Rogasi PG et al. Radioimmunoassay of thromboxane B2 in plasma: methodological modifications. 1988 Thromb. Res. pmid:3175991
Schorer AE Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. 1997 Thromb. Res. pmid:9062953
Kosaki G et al. The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins. I. The effect on the release of arachidonic acid from phospholipids. 1980 Dec 1-15 Thromb. Res. pmid:6785893
Butler KD et al. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. 1987 Thromb. Res. pmid:3109067
Anfossi G et al. Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. 1995 Thromb. Res. pmid:7778055
Watanabe T et al. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. 2001 Thromb. Res. pmid:11672751
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Lee GY et al. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester. 2005 Thromb. Res. pmid:15668191
Ziegler BK et al. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. 2001 Thromb. Res. pmid:11672759
Ljungberg B et al. Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors. 1988 Thromb. Res. pmid:2847353
Boyd JA and Eling TE Prostaglandin release and the interaction of platelets with the pulmonary vasculature of rat and guinea pig. 1980 Jul 1-15 Thromb. Res. pmid:7003800
Ersöz G et al. The effect of submaximal exercise on platelet aggregation during late follicular and midluteal phases in women. 2002 Thromb. Res. pmid:12590951
Martin JF et al. Effect of acetylsalicylic acid on platelet aggregation and thromboxane B2 production in flowing aortic blood in the rat studied with a filter loop technique. 1982 Thromb. Res. pmid:6814004
Mikashima H and Muramoto Y Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. 1990 Thromb. Res. pmid:2326771
Agren JJ et al. Dose responses in platelet fatty acid composition, aggregation and prostanoid metabolism during moderate freshwater fish diet. 1990 Thromb. Res. pmid:2326774
Kawamura M et al. Evaluation of plasma 11-dehydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. 1995 Thromb. Res. pmid:7778061
Ersöz G et al. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats. 2003 Thromb. Res. pmid:14698654
Addonizio VP et al. Inhibition of human platelet function by verapamil. 1982 Thromb. Res. pmid:7164035
Pekonen F et al. Platelet function and coagulation in normal and preeclamptic pregnancy. 1986 Thromb. Res. pmid:2944245
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Grauso F et al. Effects of iloprost (ZK 36374), a prostacyclin derivative, on platelet function after ischaemic exercise in patients with stable angina pectoris. 1987 Thromb. Res. pmid:2447664
Vlodavsky I et al. Platelet interaction with the extracellular matrix produced by cultured endothelial cells: a model to study the thrombogenicity of isolated subendothelial basal lamina. 1982 Thromb. Res. pmid:7179215
Saldeen P et al. Thromboxane production in umbilical vein grafts. 1984 Thromb. Res. pmid:6546814
Udvardy M et al. Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus. 1987 Thromb. Res. pmid:3116717
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
Umemura K et al. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model. 1995 Thromb. Res. pmid:7660354
Carter AJ et al. Human pulmonary vessels obtained from necropsy produce less prostacyclin and thromboxane than fresh vessels obtained from operations. 1984 Thromb. Res. pmid:6547546
Rousson D et al. Acute myocardial infarction: measurement of arachidonate end-products in whole blood as an index of platelet cyclo-oxygenase activity in vivo. 1987 Thromb. Res. pmid:3122356
Navran SS et al. Human platelet activation by bacterial phospholipase C is mediated by phosphatidylinositol hydrolysis but not generation of phosphatidic acid: inhibition by a selective inhibitor of phospholipase C. 1984 Thromb. Res. pmid:6372157
Shorr RI et al. In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis. 1985 Thromb. Res. pmid:3923647
Vanags D et al. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery. 1990 Thromb. Res. pmid:2264023
Cerskus AL et al. Thromboxane B2 and 6-keto-prostaglandin F1 alpha synthesis during infusion of collagen and arachidonic acid in rabbits: inhibition by aspirin and sulfinpyrazone. 1980 Thromb. Res. pmid:7414555
Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. 1991 Thromb. Res. pmid:1754998
Castaldi PA et al. Evidence for a platelet membrane defect in the myeloproliferative syndromes. 1982 Thromb. Res. pmid:6960545
Kankuri E et al. Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. 2003 Thromb. Res. pmid:14592552
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Toivanen J et al. Differential inhibition of platelet thromboxane and lung prostacyclin production by sulphinpyrazone, acetylsalicylic acid and indomethacin by human tissues in vitro. 1985 Thromb. Res. pmid:3920778
Mercer JB et al. The effect of short-term cold exposure on risk factors for cardiovascular disease. 1999 Thromb. Res. pmid:10418798
Perneby C et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 Thromb. Res. pmid:15381386
Hall ER et al. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits. 1982 Thromb. Res. pmid:6891109
Lukasik M et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. 2011 Thromb. Res. pmid:21788065
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Arruzazabala ML et al. Effects of Policosanol on platelet aggregation in rats. 1993 Thromb. Res. pmid:8475481
Riess H et al. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. 1984 Thromb. Res. pmid:6237460
Cattaneo M et al. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. 1991 Thromb. Res. pmid:1926062
Patrono C et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 1980 Feb 1-15 Thromb. Res. pmid:7368167
Lin CH et al. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets. 1992 Thromb. Res. pmid:1412184
Koh H et al. A radioimmunoassay of thromboxane B2 with thromboxane B2-125I-tyramide and its application to the study on the thromboxane B2 formation during platelet aggregation. 1980 Feb 1-15 Thromb. Res. pmid:7368170
Tindall H et al. Thrombin generation precedes platelet activation in native blood taken from the hand during multiple blood sampling following cold challenge. 1987 Thromb. Res. pmid:3617016
Kohda N et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. 1999 Thromb. Res. pmid:10593428
Deckmyn H et al. Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure. 1983 Thromb. Res. pmid:6344317
Mannucci L et al. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. 1987 Thromb. Res. pmid:3445229
Nosál' R et al. Chloroquine: a multipotent inhibitor of human platelets in vitro. 2000 Thromb. Res. pmid:10828481
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Vesterqvist O et al. Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. 1984 Thromb. Res. pmid:6695361
Lee TK et al. Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke. 1987 Thromb. Res. pmid:3629557
Tanoue K et al. A new variant of thrombasthenia with abnormally glycosylated GP IIb/IIIa. 1987 Thromb. Res. pmid:3629560
Zijlstra FJ et al. Thrombotic thrombocytopenic purpura and plasma thromboxane B2 levels. 1983 Thromb. Res. pmid:6684333
Altman R and Scazziota A Synergistic actions of paf-acether and sodium arachidonate in human platelet aggregation. 2. Unexpected results after aspirin intake. 1986 Thromb. Res. pmid:3088757
Petroni A et al. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. 1995 Thromb. Res. pmid:7482432
De La Cruz JP et al. Antithrombotic potential of olive oil administration in rabbits with elevated cholesterol. 2000 Thromb. Res. pmid:11113274
Barnhart MI et al. DDAVP: does the drug have a direct effect on the vessel wall? 1983 Thromb. Res. pmid:6415852
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Teng CM et al. Inhibition of thrombin- and collagen-induced phosphoinositides breakdown in rabbit platelets by a PAF antagonist--denudatin B, an isomer of kadsurenone. 1990 Thromb. Res. pmid:2169076
Pattison A et al. The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood. 1986 Thromb. Res. pmid:3755259
Maguire ED and Wallis RB In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. 1983 Thromb. Res. pmid:6689221
Russell NH et al. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. 1981 Thromb. Res. pmid:6794179
Di Minno MN et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. 2011 Thromb. Res. pmid:21669453
Lagarde M et al. Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. 1980 Thromb. Res. pmid:7466751
Ames PR et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. 2012 Thromb. Res. pmid:22521214
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Hofmann D et al. Evidence for sustained platelet activation in patients with early postinfarction angina. 1993 Thromb. Res. pmid:8303651
Toft G et al. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. 2000 Thromb. Res. pmid:10904104
Korth R et al. Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. 1986 Thromb. Res. pmid:3961742
Pinto S et al. No signs of increased thrombin generation in menopause. 1990 Thromb. Res. pmid:2201101
Riess H et al. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. 1986 Thromb. Res. pmid:3012819
Randall MJ et al. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. 1981 Jul 1-15 Thromb. Res. pmid:6795753
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Teng CM et al. Platelet aggregation induced by equinatoxin. 1988 Thromb. Res. pmid:2906181
Selley ML et al. The effect of cholesterol oxidation products on human platelet aggregation. 1996 Thromb. Res. pmid:8885139
Kritz H et al. Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished. 1995 Thromb. Res. pmid:8610276
De Caterina R et al. Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. 1990 Thromb. Res. pmid:2126400
Lai LJ et al. Trilinolein inhibits epinephrine-induced human platelet aggregation. 1994 Thromb. Res. pmid:7863478
Wang JP et al. XC 386: a new antiplatelet agent. 1984 Thromb. Res. pmid:6438827
Perneby C et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. 1999 Thromb. Res. pmid:10632465
Prosdocimi M et al. Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery. 1985 Thromb. Res. pmid:3840290
Carter AJ and Jones EW The effect of the degree of diabetic control on thromboxane synthesis in clotted whole blood. 1986 Thromb. Res. pmid:3515613
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Neiman J et al. Platelet uptake of serotonin (5-HT) during ethanol withdrawal in male alcoholics. 1987 Thromb. Res. pmid:2820078
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Ko FN et al. Antiplatelet effects of protopine isolated from Corydalis tubers. 1989 Thromb. Res. pmid:2559491
Swart SS et al. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. 1984 Thromb. Res. pmid:6326344
Ito T et al. Role of activated platelets in endotoxin-induced DIC in rats. 1990 Thromb. Res. pmid:2080492
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Lukaszyk A et al. Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). 1992 Thromb. Res. pmid:1579898
Meyers KM et al. An evaluation of the arachidonate pathway of platelets from companion and food-producing animals, mink, and man. 1980 Thromb. Res. pmid:7209869